Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Dean Li, president of Merck Research Laboratories, told the meeting that ... but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck acquired ...

Merck & Co’s – known as MSD outside of the US and Canada – Welireg (belzutifan) has been conditionally approved by the ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Germany’s Merck KGaA has appointed three new members to its executive board, which it says is a natural evolution in the company’s leadership as it continues to implement its growth strategy.

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a cautious approach to buying other companies, which are expensively priced.

The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.